AHF: The G20 Manifesto Calls on Leaders to Vaccinate Our World!

AHF: The G20 Manifesto Calls on Leaders to Vaccinate Our World!




AHF: The G20 Manifesto Calls on Leaders to Vaccinate Our World!

LOS ANGELES–(BUSINESS WIRE)–In an urgent appeal for global health solidarity and equitable vaccine access, AIDS Healthcare Foundation (AHF) is launching a G20 Manifesto and a ticking clock counting down to the G20 summit in Rome, Italy, this October. The Manifesto outlines seven actions G20 leaders must take before the meeting to Vaccinate Our World and put the world on a path to defeating the pandemic. The full text of the Manifesto and the clock are viewable on the campaign website at www.vaccinateourworld.org/.


Even though lifesaving vaccines are available in a handful of wealthy countries, the majority of people around the world – particularly in Africa and Asia – simply have no access to them. COVAX, which was supposed to be a vaccine lifeline for lower-income countries, has fallen far short of the need, which is why the G20 must do more to ramp up vaccine production and distribution worldwide. If there is even just one country left unprotected from COVID-19, no country is safe.

“It’s paramount that the G20 immediately begin implementing real actions that can correct the vaccine disparities plaguing most countries,” said Terri Ford, Chief of Global Advocacy and Policy at AHF. “We’re issuing this Manifesto and starting a countdown to the G20 summit in Rome because there is currently no sense of urgency to vaccinate our world. G20 leaders must be the catalyst for ensuring global vaccine equity, and their annual meeting is the ideal venue to make it happen. Anything less would be an injustice and all but guaranteeing millions more preventable deaths.”

The G20 Manifesto lists specific actions that can help get lifesaving vaccines to everyone who needs them. They are as follows:

AHF calls on everyone to join the fight for fair vaccine access by reading and sharing the G20 Manifesto as far and wide as possible, then pledging to protect all humanity at vaccinateourworld.org. Together, we can convince G20 leaders to step up and end this pandemic!

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to over 1.5 million clients in 45 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare

Contacts

US MEDIA CONTACT:

Ged Kenslea, Senior Director, Communications, AHF

+1.323.308.1833 work +1.323.791.5526 mobile

gedk@aidshealth.org

Denys Nazarov, Director of Global Policy &

Communications, AHF

+1 323.308.1829

denys.nazarov@ahf.org

ReCode Therapeutics to Present Preclinical Data from mRNA-Based Program for Primary Ciliary Dyskinesia at the 2021 PCD on the Move Virtual Scientific Conference

ReCode Therapeutics to Present Preclinical Data from mRNA-Based Program for Primary Ciliary Dyskinesia at the 2021 PCD on the Move Virtual Scientific Conference




ReCode Therapeutics to Present Preclinical Data from mRNA-Based Program for Primary Ciliary Dyskinesia at the 2021 PCD on the Move Virtual Scientific Conference

MENLO PARK, Calif. & DALLAS–(BUSINESS WIRE)–#PCDReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced preclinical data from the Company’s inhaled mRNA-based molecular therapy program for primary ciliary dyskinesia will be presented in an oral and poster presentation at the 2021 PCD on the Move Virtual Scientific Conference, which is being held virtually on Thursday, August 5, 2021 at 11:45 am ET.

Archived replays of each presentation will be made available on the Company’s website following the presentations.

About ReCode Therapeutics

ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using powerful LNP delivery technology to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.

Contacts

Media Contact:
Will Zasadny

Canale Communications, Inc.

will.zasadny@canalecomm.com
(619) 961-8848

Investor Contact:
Sarah McCabe

Stern Investor Relations

sarah.mccabe@sternir.com
IR@recodetx.com

Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021

Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021




Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021

ARDSLEY, N.Y.–(BUSINESS WIRE)–Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its second quarter 2021 update and financial results on Thursday, August 5 at 4:30 p.m. ET.

To participate in the Webcast/Conference Call, please use the following pre-registration links:

Once you have registered, you will receive a confirmation email with Webcast/Conference Call details. For the Webcast, you will receive an email 2 hours prior to the start of the call with the link to join. The presentation will be available on the Investors section of www.acorda.com.

A replay of the call will be available from 7:30 p.m. ET on August 5, 2021 until 11:59 p.m. ET on September 4, 2021. To access the replay, please dial (845) 709 8569 (domestic) or +44 20 3936 3001 (international); reference code 373556. The archived webcast will be available in the Investor Relations section of the Acorda website at www.acorda.com.

About Acorda Therapeutics

Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Forward-Looking Statements

This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including: we may not be able to successfully market AMPYRA, INBRIJA or any other products under development; the COVID-19 pandemic, including related quarantines and travel restrictions, and the potential for the illness to affect our employees or consultants or those that work for other companies we rely upon, could have a material adverse effect on our business operations or product sales; our ability to raise additional funds to finance our operations, repay outstanding indebtedness or satisfy other obligations, and our ability to control our costs or reduce planned expenditures; risks associated with the trading of our common stock and our reverse stock split; risks related to our workforce, including our ability to realize the expected benefits of our corporate restructuring; risks associated with complex, regulated manufacturing processes for pharmaceuticals, which could affect whether we have sufficient commercial supply of INBRIJA to meet market demand; our reliance on third-party manufacturers for the production of commercial supplies of AMPYRA and INBRIJA; third-party payers (including governmental agencies) may not reimburse for the use of INBRIJA at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; reliance on collaborators and distributors to commercialize INBRIJA and AMPYRA outside the U.S.; competition for INBRIJA and AMPYRA, including increasing competition and accompanying loss of revenues in the U.S. from generic versions of AMPYRA (dalfampridine) following our loss of patent exclusivity; the ability to realize the benefits anticipated from acquisitions, among other reasons because acquired development programs are generally subject to all the risks inherent in the drug development process and our knowledge of the risks specifically relevant to acquired programs generally improves over time; the risk of unfavorable results from future studies of INBRIJA (levodopa inhalation powder) or from other research and development programs, or any other acquired or in-licensed programs; the occurrence of adverse safety events with our products; the outcome (by judgment or settlement) and costs of legal, administrative or regulatory proceedings, investigations or inspections, including, without limitation, collective, representative or class-action litigation; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third-party intellectual property licenses needed for the commercialization of our products; and failure to comply with regulatory requirements could result in adverse action by regulatory agencies.

These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this press release are made only as of the date hereof, and we disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Contacts

Tierney Saccavino

(914) 326-5104

tsaccavino@acorda.com

GEHA Extends Vaccination Incentive Program to Encourage U.S. COVID-19 Vaccinations

GEHA Extends Vaccination Incentive Program to Encourage U.S. COVID-19 Vaccinations




GEHA Extends Vaccination Incentive Program to Encourage U.S. COVID-19 Vaccinations

GEHA Vaccination Incentive Program Extended to September 6, 2021

LEE’S SUMMIT, Mo.–(BUSINESS WIRE)–Today GEHA (pronounced G. E. H. A.) announced it will extend the previously launched COVID-19 Vaccination Incentive Program for GEHA medical plan members to September 6, 2021.

GEHA members will have the opportunity to utilize the extended incentive program, which provides eligible members a $75 wellness account credit for receiving a full COVID-19 vaccine.

On July 29th, President Biden called on state and local governments to use COVID-19 relief funds to give $100 to residents who get vaccinated and said federal workers will have to show proof of vaccination or face new restrictions in the workplace, including complying with weekly testing. GEHA members have the opportunity to secure both the GEHA incentive and their state and local government’s depending on where they reside.

“GEHA is committed to the health and safety of the U.S. federal workforce in the wake of the COVID-19 pandemic. Extending the Vaccination Incentive Program is paramount to our commitment to our members and their families,” said Interim President and CEO of GEHA Rich Bierman.

“Federal workers are the backbone of our nation’s infrastructure, and our vaccination incentive program is designed to support them and their families during this critical time.”

Tens of thousands of members have participated in the Vaccination Incentive Program since launched earlier this month. The goal of the program is to continually encourage eligible members within the Federal Employees Health Benefits (FEHB) Program to be vaccinated against COVID-19.

Program participants can use the Vaccination Incentive Program $75 credit on qualified medical expenses such as office visits, co-pays, prescription drugs, eyeglasses, contacts and X-rays.

Eligible members are able to sign up for GEHA’s COVID-19 Vaccination Incentive Program and submit proof of vaccination. Eligible members are GEHA medical plan members who are 18 years of age and older, enrolled in a GEHA wellness program and have not reached their annual wellness program reward limit*.

When eligible members provide proof of their COVID-19 vaccination, they will receive a $75 credit to their GEHA wellness account. To be eligible to receive the incentive, the first COVID-19 vaccination must occur on or before September 6, 2021. Program participants will then have until Dec. 31, 2021, to show proof of complete vaccination. The program is retroactive to 2020 so all eligible GEHA members who received a COVID-19 vaccine prior to September 6, 2021, may also provide proof of their vaccine status to receive a $75 credit to their GEHA wellness account.

Additional eligibility information, proof of vaccination and program sign up will be available at geha.com/covid-19.

*The Vaccine Incentive Program credit will be the lesser of $75 or the amount remaining to meet the eligible member’s annual wellness program reward limit.

ABOUT GEHA

GEHA (Government Employees Health Association, Inc., pronounced G.E.H.A.), founded in 1937, is a non-profit member association and the largest dental and second largest medical benefit provider of federal employees exclusively serving 2 million current employees and retirees, military retirees, and their families. GEHA’s mission, to empower members to be healthy and well, is demonstrated through its focus on innovation as well as providing members with access to one of the largest medical provider networks nationwide.

Headquartered in Lee’s Summit, Missouri, GEHA is one of the largest employers in the Kansas City metro area. For more information, visit geha.com.

Contacts

Cristi Allen (GEHA) / 816-679-4387

Lisa Ketteler (GEHA) / 816-305-5822

NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19

NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19




NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19

  • ACTIV-5/BET-B trial amended in the context of Humanigen’s positive Phase 3 lenzilumab LIVE-AIR study
  • Primary endpoint focuses on survival without ventilation by day 28 in patients with baseline C-reactive protein (CRP) levels less than 150 mg/L
  • Study modification may enable Humanigen to use ACTIV-5/BET-B as a confirmatory study to support a future Biologics License Application (BLA)
  • Approximately half of the 400 patients are already enrolled in ACTIV-5/BET-B

BURLINGAME, Calif.–(BUSINESS WIRE)–Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company developing a first-in-class GM-CSF neutralizing antibody to prevent and treat an immune hyper-response called ‘cytokine storm’ across multiple therapeutic indications, has announced that the NIH has advanced the ACTIV-5/BET-B study to a Phase 2/3 study and modified the primary endpoint to survival without ventilation (“SWOV”), the same endpoint used in the Phase 3 LIVE-AIR study.

The amended ACTIV-5/BET-B study now includes 400 patients overall. Up to sixty US sites will be participating in the study. Humanigen is providing lenzilumab and assisting the NIH to achieve the timely completion of the study. NIH is sponsoring and funding this study.

“We appreciate the close collaboration with NIH on this important study,” said Adrian Kilcoyne, MD, Chief Medical Officer, Humanigen. “The ACTIV-5/BET-B study design has been adapted to align with the design of LIVE-AIR and may help support a future BLA for lenzilumab.”

“Sharing the same endpoint as the LIVE-AIR study, the ACTIV-5/BET-B study reinforces the potential for lenzilumab to treat hospitalized COVID-19 patients,” said Vincent Marconi, MD, Professor of Medicine at Emory University School of Medicine. “At Emory University, a key center in both the LIVE-AIR and ACTIV-5/BET-B studies, we believe these trials can identify the optimal patient population for lenzilumab. LIVE-AIR showed us that COVID-19 patients who at baseline had a CRP of less than 150 mg/L and are under 85 years of age had the greatest response to lenzilumab. Using CRP as a biomarker to identify COVID-19 patients at risk for disease progression, in whom lenzilumab treatment can be initiated prior to full blown cytokine storm, would be lifesaving.”

“ACTIV-5/BET-B may provide prospective validation for lenzilumab in the treatment of COVID-19,” said Cameron Durrant, MD, Chief Executive Officer, Humanigen. “We believe ACTIV-5/BET-B, along with LIVE-AIR, will provide the sufficient size and statistical power typically required for a BLA to be submitted to FDA.”

About ACTIV-5/BET-B

The Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV) is a National Institutes of Health (NIH) directed public-private partnership to develop a coordinated research strategy for prioritizing and speeding development of the most promising treatments and vaccines.1 ACTIV is led by a working group of senior scientists representing government, industry, non-profit, philanthropic, and academic organizations and is pursuing five fast-track focus areas most ripe for opportunity, one of which is accelerating clinical testing of the most promising vaccines and treatments. Within this focus area ACTIV-5 (Big Effect Trial, BET) is a series of randomized, double-blind, placebo-controlled trials using common assessments and endpoints to evaluate whether certain therapies, approved or investigational, show promise against COVID-19.

Within ACTIV-5, lenzilumab is the first and only anti-human GM-CSF treatment to be tested in ACTIV-5 as a concomitant therapy with remdesivir compared with remdesivir alone. Lenzilumab was selected from among 400 compounds that were considered for investigation in ACTIV.2 The study began in October 2020 and was comprised of 200 adult hospitalized patients who need medical care for COVID-19 pneumonia and randomized (1:1) to the treatment groups.2 Patients receive a loading dose of 200-mg intravenous (IV) remdesivir on day 1 followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized. Lenzilumab (or placebo) is administered at 600-mg IV lenzilumab infusion every 8 hours starting on Day 1 for a total of 3 doses.2 The original primary efficacy outcome was change in clinical status on an 8-point ordinal scale at Day 8 from the NIH-sponsored Adaptive COVID-19 Treatment Trial (ACTT, NCT 04280705).3,4

Lenzilumab Clinical Evidence Supporting Modification of ACTIV-5/BET-B

Lenzilumab achieved the primary endpoint of the Phase 3 LIVE-AIR trial with a 1.54-fold relative improvement in the likelihood of SWOV compared to placebo. Lenzilumab also improved the relative likelihood of SWOV by 1.92-fold in the pre-specified subgroup of subjects who received both corticosteroids and remdesivir as well as a 3-fold improvement in the likelihood of SWOV in patients with a baseline CRP<150 mg/L and less than 85 years of age. In these patients, a 2.2-fold improvement in the likelihood of survival was observed with lenzilumab. No serious adverse events were attributed to lenzilumab, and the overall safety profile was comparable to placebo.

The LIVE-AIR, Phase 3 Study was a randomized, double-blind, placebo-controlled, multi-center Phase 3 trial for the treatment and prevention of serious and potentially fatal outcomes in patients who were hospitalized with COVID-19 pneumonia. The primary objective was to assess whether lenzilumab, in addition to other treatments, which included dexamethasone (or other steroids) and/or remdesivir, could alleviate the immune-mediated cytokine release syndrome (CRS) and improve SWOV. SWOV is a composite endpoint of time to death and time to IMV, which is a robust measure that is less prone to favor a treatment with discordant effects on survival or days free of ventilation.1

The LIVE-AIR study enrolled 520 patients in 29 sites in the US and Brazil who were at least 18 years of age; experienced blood oxygen saturation (SpO2) of less than or equal to 94%; or required low-flow supplemental oxygen, or high-flow oxygen support, or non-invasive positive pressure ventilation (NIPPV); and were hospitalized but did not require IMV. Following enrollment, subjects were randomized to receive three infusions of either lenzilumab or placebo, each infusion separated by eight hours over a 24-hour period with other treatments. The primary endpoint was the difference between lenzilumab treatment and placebo treatment in SWOV through 28 days following treatment. Key secondary endpoints, also measured through 28 days, included ventilator-free days, duration of ICU stay, incidence of IMV, extracorporeal membrane oxygenation (ECMO), and/or death, time to death, all-cause mortality, and time to recovery. LIVE-AIR results have been submitted for potential publication in a peer-reviewed journal.

About Lenzilumab

Lenzilumab is a proprietary Humaneered® (“Humaneered”) first-in-class monoclonal antibody that has been proven to neutralize GM-CSF, a cytokine of critical importance in the hyperinflammatory cascade, sometimes referred to as cytokine release syndrome (“CRS”) or cytokine storm (CS), associated with COVID-19 and other indications. Lenzilumab binds to and neutralizes GM-CSF, consequently improving outcomes for hypoxic patients hospitalized with COVID-19. Humanigen believes that its GM-CSF neutralization has the potential to reduce the hyper-inflammatory cascade known as cytokine release syndrome common to chimeric antigen receptor T-cell (CAR-T) therapy and acute Graft versus Host Disease (aGvHD).

In CAR-T, lenzilumab successfully achieved pre-specified primary endpoint at the recommended dose in a Phase 2 study with Yescarta in which the overall response rate was 100% and no patient experienced severe cytokine release syndrome or severe neurotoxicity. Based on these results, Humanigen plans to test lenzilumab in a randomized, multicenter, potentially registrational, Phase 2 study to evaluate its efficacy and safety when combined with all commercially available CD19 CAR-T therapies in DLBCL. Lenzilumab will also be tested to assess its ability prevent and/or treat aGvHD in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).

About Humanigen

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of inflammation and immuno-oncology. Humanigen’s immediate focus is to prevent or minimize cytokine release syndrome that precedes severe lung dysfunction in hospitalized and hypoxic patients with COVID-19 pneumonia. Humanigen has requested Emergency Use Authorization for this indication and is submitting lenzilumab to the Medicines and Health Regulatory Agency in the United Kingdom under an expedited rolling review seeking Marketing Authorization. Humanigen is also exploring the effectiveness of lenzilumab in other inflammatory conditions such as aGvHD and cytokine release syndrome associated with CAR-T. For more information, visit www.humanigen.com and follow Humanigen on LinkedIn, Twitter, and Facebook.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as “will,” “expect,” “intend,” “plan,” “potential,” “possible,” “goals,” “accelerate,” “continue,” and similar expressions identify forward-looking statements, including, without limitation, statements regarding our request for and receipt of an Emergency Use Authorization from FDA for lenzilumab in COVID-19; our request and receipt of Marketing Authorization or Conditional Marketing Authorization for lenzilumab in COVID-19 by the MHRA; and our other plans relating to lenzilumab to further development of lenzilumab.

Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the “Risk Factors” sections of our latest annual and quarterly reports and other filings with the SEC.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. We undertake no obligation to revise or update any forward-looking statements made in this presentation to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law.

References

  1. National Institutes of Health. (n.d.). “ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS AND VACCINES (ACTIV).” https://www.nih.gov/research-training/medical-research-initiatives/activ.
  2. Collins, D. F. (2021, February 16). ACTIV Update: Making major strides in covid-19 Therapeutic Development. NIH Director’s Blog. https://directorsblog.nih.gov/2021/02/16/activ-update-making-major-strides-in-covid-19-therapeutic-development/ (accessed July 30, 2021)
  3. The National Library of Medicine – ClinicalTrials.gov (2021, July 9). ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19. https://www.clinicaltrials.gov/ct2/show/NCT04583969.
  4. Beigel J.H., Tomashek K.M., Dodd L.E., et al. (2020). Remdesivir for the Treatment of COVID-19 — Final Report. New England Journal of Medicine, 383(19), 1813–1826. https://doi.org/10.1056/nejmoa2007764.

Contacts

Humanigen Media
Grace Catlett

RXMD

Gcatlett@rxmedyn.com
516-318-8563

Humanigen Investor Relations
Ken Trbovich

Humanigen

trbo@humanigen.com
650-410-3206

Global CBD-infused Products Market (2020 to 2028) – by Source, Type, and Distribution Channel – ResearchAndMarkets.com

Global CBD-infused Products Market (2020 to 2028) – by Source, Type, and Distribution Channel – ResearchAndMarkets.com




Global CBD-infused Products Market (2020 to 2028) – by Source, Type, and Distribution Channel – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “CBD-infused Products Market by Source, Type, and Distribution Channel – Global Forecast to 2028” report has been added to ResearchAndMarkets.com’s offering.

This research report provides an in-depth analysis of the CBD-infused products market across five major geographies and emphasizes on the current market trends, market size, market shares, recent developments, and forecast till 2028. The CBD-infused Products Market is expected to reach $216.8 billion by 2028, at a CAGR of 45.6% during the forecast period, 2021-2028.

The growth of this market is mainly attributed to the rising demand and increasing legalization of cannabis, growing application of cannabis in cancer, and health benefits offered by cannabis-infused products are also a few of the key factors driving the growth of the CBD-infused products market.

The study offers a comprehensive analysis of the CBD-infused products market with respect to the source (hemp and marijuana), type (CBD-edibles {confectionery products, bakery products, beverages [non-alcoholic beverages and alcoholic beverages], coffee & tea products, and other products}, CBD-oil and extracts, CBD-personal care products {skincare products, haircare products, deodorants and perfumes, and other personal care products}, CBD-smoke & vape products, CBD-supplements, CBD-pet products, and other CBD-products), distribution channel (offline store {dispensary, pharmacies, natural health foods store, and other stores} and online store), and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Companies Mentioned

  • Canopy Growth Corporation
  • Aurora Cannabis Inc.
  • Docklight Brands Inc.
  • Maricann Inc.
  • Tilray Inc.
  • GW Pharmaceuticals plc
  • VIVO Cannabis Inc.
  • Cresco Labs Inc.
  • Tauriga Sciences Inc.
  • MariMed Inc.
  • CV Sciences Inc.
  • Puration Inc.
  • Kona Gold Solutions Inc.
  • Bhang Inc.
  • DT Brands & Co Ltd.
  • Forest Coffee Trading Co.
  • L8 Life Inc.
  • Honeydrop Beverages Inc.
  • Elixinol Global Limited

     

Key Questions Answered in the Report

  • Which are the high-growth market segments in terms of source, type, distribution channel, and geography?
  • What is the historical market size for the CBD-infused products market?
  • What are the market forecasts and estimates for the period 2021-2028?
  • What are the major drivers, restraints, opportunities, and challenges in the CBD-infused products market?
  • Who are the major players in the market, and what share of the market do they hold?
  • Who are the major players in various countries, and what share of the market do they hold?
  • How is the competitive landscape for the CBD-infused products market?
  • What are the recent developments in the CBD-infused products market?
  • What are the different strategies adopted by the major players in the market?
  • What are the key geographic trends, and which are the high-growth countries?
  • Who are the local emerging players in the CBD-infused products market, and how do they compete with the other players?

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Insights

4.1. Introduction

4.2. Drivers

4.2.1. Rising Demand and Increasing Legalization of Cannabis

4.2.2. Growing Application of Cannabis in Cancer

4.2.3. Health Benefits offered by Cannabis-infused Products

4.3. Restraints

4.3.1. High Cost Associated with Cannabidiol (CBD)

4.3.2. Stringent Government Regulations against Cannabis in Certain Countries

4.4. Opportunities

4.4.1. Usage of Cannabis in Pet Food

4.4.2. Increasing Demand for Cannabis in Drinks and Sports Nutrition

4.5. Challenges

4.5.1. Health Risks Associated with Over Consumption of CBD

4.6. Impact of Covid-19 on the CBD-infused Products Market

5. Global CBD-infused Products Market, by Source

5.1. Hemp

5.2. Marijuana

6. Global CBD-infused Products Market, by Type

6.1. Introduction

6.2. Edibles

6.2.1. Confectionery Products

6.2.2. Bakery Products

6.2.3. Beverages

6.2.4. Coffee & Tea Products

6.2.5. Other Edible Products

6.3. Oil & Extracts

6.4. Personal Care Products

6.4.1. Skincare Products

6.4.2. Haircare Products

6.4.3. Deodorants & Perfumes

6.4.4. Other Personal Care Products

6.5. Smoke & Vape Products

6.6. Supplements

6.7. Other CBD Products

7. Global CBD-infused Products Market, by Distribution Channel

7.1. Introduction

7.2. Offline Store

7.2.1. Dispensaries

7.2.2. Pharmacies

7.2.3. Natural Health Food Stores

7.2.4. Other Stores

7.3. Online Stores

8. CBD-infused Products Market, by Geography

9. Competitive Landscape

9.1. Introduction

9.2. Key Growth Strategies

9.3. Competitive Benchmarking

10. Company Profiles

11. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/z0j2fh

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Global Contraceptives Market Forecast to 2028 – COVID-19 Impact and Analysis – ResearchAndMarkets.com

Global Contraceptives Market Forecast to 2028 – COVID-19 Impact and Analysis – ResearchAndMarkets.com




Global Contraceptives Market Forecast to 2028 – COVID-19 Impact and Analysis – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Contraceptives Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product, End User, Distribution Channel” report has been added to ResearchAndMarkets.com’s offering.

The contraceptives market is expected to reach US$ 29,629.4 million in 2028 from US$ 20,825.0 million in 2020; it is estimated to grow at a CAGR of 4.50% from 2020 to 2028.

The growth of the contraceptives market is mainly attributed to increasing rate of unwanted pregnancies and surge in product innovations and launches. However, lack of adoption in low income countries is projected to deter the market growth.

Sexually transmitted diseases (STDs) have a major impact on sexual and reproductive health worldwide. As per the WHO, more than 1 million sexually transmitted infections (STIs) are acquired every day worldwide. Each year, ~376 million new infections with chlamydia, gonorrhea, syphilis, and trichomoniasis are reported. Contraceptive methods alter the risk of acquiring STDs. For instance, spermicides have been reported to kill a wide range of bacteria and viruses, including HIV, in vitro; moreover, they have been reported to provide protection against gonorrhea, chlamydia, and pelvic inflammatory disease in vivo. Condoms and diaphragms also provide a certain level of protection from bacterial and viral infections.

Growing awareness through government initiatives and sex education programs to reduce the prevalence of STDs offers lucrative opportunities for the growth of the contraceptives market players. Various governments are promoting the use of condoms to prevent unwanted pregnancies and preventing STDs. For instance, the Centers for Disease Control and Prevention (CDC) has Condom distribution programs (CDPs) to prevent HIV and STDs. The program helps in increasing the availability and accessibility of condoms.

Based on product, the contraceptives market is segmented into condoms, intrauterine product (IUDs), vaginal rings, implants, patches, diaphragms, emergency contraceptives, sponges, and others. The condoms segment held the largest share of the market in 2020, whereas the intrauterine product (IUDs) segment is anticipated to register the highest CAGR in the market during the forecast period. Based on end user, the contraceptives market is segmented into home care, and hospitals and clinics. Based on distribution channel, the contraceptives market has been segmented into retail pharmacy, online pharmacy, and hospital pharmacy.

Market Dynamics

Drivers

  • Increasing Rate of Unwanted Pregnancies
  • Surge in Product Innovations and Launches

Restraints

  • Lack of Adoption in Low Income Countries

Opportunities

  • Increasing Awareness About Sexually Transmitted Diseases

Future Trends

  • Digital Fertility Methods for Family Planning

Companies Mentioned

  • Bayer AG
  • Cooper Companies Inc.
  • Merck & Co. Inc
  • HLL Lifecare Limited
  • Church & Dwight Inc.
  • Pregna International Limited
  • Mayer Laboratories Inc.
  • Medicines360
  • Prosan International B.V.
  • Cupid Limited

For more information about this report visit https://www.researchandmarkets.com/r/sn5iup

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Worldwide In-vitro Transcription Templates Industry to 2030 – by Disease, Treatment, Research Stage, End-user and Region – ResearchAndMarkets.com

Worldwide In-vitro Transcription Templates Industry to 2030 – by Disease, Treatment, Research Stage, End-user and Region – ResearchAndMarkets.com




Worldwide In-vitro Transcription Templates Industry to 2030 – by Disease, Treatment, Research Stage, End-user and Region – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “In-vitro Transcription Templates Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030” report has been added to ResearchAndMarkets.com’s offering.

This report on the global in-vitro transcription templates market studies past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2020 to 2030. The report provides revenue of the global in-vitro transcription templates market for the period of 2018-2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global in-vitro transcription templates market during the forecast period.

The report has been prepared after primary and secondary researches. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global in-vitro transcription templates market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomenon in the global in-vitro transcription templates market.

The report includes an elaborate executive summary along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global in-vitro transcription templates market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global in-vitro transcription templates market.

The report delves into the competitive landscape of the global in-vitro transcription templates market. Key players operating in the global in-vitro transcription templates market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global in-vitro transcription templates market that have been profiled in this report.

Key Questions Answered in the Report

  • What is the scope of growth for product companies in the global in-vitro transcription templates market?
  • What will be the Y-o-Y growth of the global in-vitro transcription templates market between 2020 and 2030?
  • What is the influence of changing trends in technologies on the global in-vitro transcription templates market
  • Will North America continue to be the most profitable market for in-vitro transcription templates?
  • Which factors are anticipated to hamper the global in-vitro transcription templates market during the forecast period?
  • Which are the leading companies in the global in-vitro transcription templates market?

Key Topics Covered:

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary: Global In-vitro Transcription Templates Market

4. Market Overview

4.1. Introduction

4.1.1. Disease Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global In-vitro Transcription Templates Market Analysis and Forecast, 2017-2031

4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

5.1. Technological Advancements

5.2. Major Research Institutes Involved

5.3. Disease Prevalence & Incidence Rate globally with key countries

5.4. Number of mRNA Templates utilized Per Year

5.5. Analysis of Purchase Criteria (vaccine/therapeutics/research)

5.5.1. Overview of Purchase Criteria

5.5.2. mRNA Size Needs

5.5.3. Synthesis Scale Needs

5.5.4. Modified Bases Needs

5.5.5. cGMP/21 CFR part 11 certification requirement assessment

5.6. COVID-19 Pandemic Impact on Industry (value chain and short / mid /long term impact)

6. Global In-vitro Transcription Templates Market Analysis and Forecast, by Disease

7. Global In-vitro Transcription Templates Market Analysis and Forecast, by Treatment

8. Global In-vitro Transcription Templates Market Analysis and Forecast, by Research Stage

9. Global In-vitro Transcription Templates Market Analysis and Forecast, by End-user

10. Global In-vitro Transcription Templates Market Analysis and Forecast, by Region

11. North America In-vitro Transcription Templates Market Analysis and Forecast

12. Europe In-vitro Transcription Templates Market Analysis and Forecast

13. Asia Pacific In-vitro Transcription Templates Market Analysis and Forecast

14. Latin America In-vitro Transcription Templates Market Analysis and Forecast

15. Middle East & Africa In-vitro Transcription Templates Market Analysis and Forecast

16. Competition Landscape

16.1. Market Player – Competition Matrix (by tier and size of companies)

16.2. Market Share Analysis by Company, 2020

16.3. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/jk2qss

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Worldwide Targeted Therapeutics Industry to 2031 – by Type, Application, Distribution Channel and Region – ResearchAndMarkets.com

Worldwide Targeted Therapeutics Industry to 2031 – by Type, Application, Distribution Channel and Region – ResearchAndMarkets.com




Worldwide Targeted Therapeutics Industry to 2031 – by Type, Application, Distribution Channel and Region – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Targeted Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031” report has been added to ResearchAndMarkets.com’s offering.

This report on the global targeted therapeutics market studies the past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period 2021 to 2031. The report provides the overall value (US$ Mn) of the global targeted therapeutics market for the period of 2017-2031, considering 2017-2019 as historical years, 2020 as the base year, and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global targeted therapeutics market for the forecast period.

The report has been prepared after an extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global targeted therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts also employed a combination of the top-down and bottom-up approaches to study various phenomena in the global targeted therapeutics market.

The report comprises an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competitive dynamics in the global targeted therapeutics market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global targeted therapeutics market. The next section of the global targeted therapeutics market report highlights the USPs, which include disease prevalence and incidence rate of cancer, clinical trial pipeline analysis, key industry events, and impact of COVID-19 on the global targeted therapeutics market.

The report delves into the competitive landscape of the global targeted therapeutics market. Key players operating in the global targeted therapeutics market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the global targeted therapeutics market report.

Companies Mentioned

  • Sanofi
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Merck KGaA
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca
  • Seagen, Inc.
  • Bayer AG
  • Amgen, Inc.
  • Bristol-Myers Squibb Company

Key Questions Answered in the Report

  • What is the sales/revenue generated by the global targeted therapeutics market across all the regions during the forecast period?
  • What are the key trends in the global targeted therapeutics market?
  • What are the major drivers, restraints, and opportunities in the global market?
  • Which region is set to expand at the fastest CAGR during the forecast period?
  • Which segment will have the highest revenue globally in 2031 and which application will expand at the fastest CAGR during the forecast period?

Key Topics Covered:

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Targeted Therapeutics Market

4. Market Overview

4.1. Introduction

4.1.1. Market Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Targeted Therapeutics Market Analysis and Forecast, 2017-2031

4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

5.1. Cancer Prevalence and Incidence Rate by Key Region

5.2. Clinical Trial Pipeline Analysis

5.3. Key Industry Events

5.4. COVID-19 Pandemics Impact on Global Targeted Therapeutics Market

6. Global Targeted Therapeutics Market Analysis and Forecast, by Type

7. Global Targeted Therapeutics Market Analysis and Forecast, by Application

8. Global Targeted Therapeutics Market Analysis and Forecast, by Distribution Channel

9. Global Targeted Therapeutics Market Analysis and Forecast, by Region

10. North America Targeted Therapeutics Market Analysis and Forecast

11. Europe Targeted Therapeutics Market Analysis and Forecast

12. Asia Pacific Targeted Therapeutics Market Analysis and Forecast

13. Latin America Targeted Therapeutics Market Analysis and Forecast

14. Middle East & Africa Targeted Therapeutics Market Analysis and Forecast

15. Competitive Landscape

15.1. Market Player – Competition Matrix (by tier and size of companies)

15.2. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/t4525y

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Insights on the Downstream Processing Global Market to 2030 – Featuring Thermo Fisher Scientific, 3M and Danaher Among Others – ResearchAndMarkets.com

Insights on the Downstream Processing Global Market to 2030 – Featuring Thermo Fisher Scientific, 3M and Danaher Among Others – ResearchAndMarkets.com




Insights on the Downstream Processing Global Market to 2030 – Featuring Thermo Fisher Scientific, 3M and Danaher Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Downstream Processing Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030” report has been added to ResearchAndMarkets.com’s offering.

The report on the global downstream processing market studies the past as well as current growth trends and opportunities to gain valuable insights of these indicators for the global market during the forecast period from 2020 to 2030. The report provides the overall revenue of the global downstream processing market from 2018 to 2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global downstream processing market for the forecast period.

The report has been prepared after extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with market leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global downstream processing market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts also employed a combination of top-down and bottom-up approaches to study various phenomena in the global downstream processing market.

The report includes an elaborate executive summary, along with a snapshot of the growth pattern of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competition dynamics in the global downstream processing market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global downstream processing market. The next section of the report highlights the USPs, which include key industry events and COVID-19 pandemic impact on the global downstream processing market.

The report delves into the competitive landscape of the global downstream processing market. Key players operating in the global downstream processing market have been identified and each one of these has been profiled for its distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the global downstream processing market report.

Companies Mentioned

  • Thermo Fisher Scientific, Inc.
  • 3M Company
  • Danaher Corporation
  • Merck KGaA
  • Lonza Group
  • Eppendorf AG
  • Sartorius AG
  • Boehringer Ingelheim International GmbH

Key Questions Answered in the Report

  • What will be the sales revenue generated by downstream processing across all regions during the forecast period?
  • What are the key trends in the global downstream processing market?
  • What are major drivers, restraints, and opportunities in the global downstream processing market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which application segment will generate the maximum revenue by 2030 and which product segment will expand at the fastest CAGR during the forecast period?

Key Topics Covered:

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary: Global Downstream Processing Market

4. Market Overview

4.1. Definition

4.2. Market Indicators

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Downstream Processing Market Value (US$ Mn) Forecast, 2018-2030

4.5. Global Downstream Processing Market Outlook

5. Key Insights

5.1. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

5.2. Key Industry Events (Merger, Acquisitions, Collaborations, Approvals, etc.) List of Key Manufacturers & Distributors, by Each Region

6. Global Downstream Processing Market Analysis and Forecast, by Technique

7. Global Downstream Processing Market Analysis and Forecast, by Product

8. Global Downstream Processing Market Analysis and Forecast, by Application

9. Global Downstream Processing Market Analysis and Forecast, by End-user

10. Global Downstream Processing Market Analysis and Forecast, by Region

11. North America Downstream Processing Market Analysis and Forecast

12. Europe Downstream Processing Market Analysis and Forecast

13. Asia Pacific Downstream Processing Market Analysis and Forecast

14. Latin America Downstream Processing Market Analysis and Forecast

15. Middle East & Africa Downstream Processing Market Analysis and Forecast

16. Competition Landscape

16.1. Market Player – Competition Matrix (by tier and size of companies)

16.2. Market Share Analysis, by Company, 2020

16.3. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/mqril6

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900